Germany's BDS goes independent:
This article was originally published in Clinica
Executive Summary
BDS International Diagnostics has been spun off from its US-based parent company, Polymedco, through a management buy-out. The new company, located in Schwetzingen, Germany, specialises in helping in vitro diagnostics and medical device suppliers to establish a foothold in European markets. Its services include searching, screening, selecting, training and managing a network of 1,800 distributors, with 650 in Europe. It also helps with regulatory issues. "Many of our international clients find it easier to meet Eastern European distributors this way, as they are often unable to attend trade fairs," George Skinner, director of sales and marketing at BDS International Diagnostics, told Clinica.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.